RPPA provided orthogonal validation of genomics analyses with evidence of MAPK activation for 76% (16/21) of patients for whom binimetinib was selected, as well as activation of c-KIT (elevated phosphorylation at Y703) for SM0009 for whom sorafenib was selected as the treatment recommendation based on both a KIT point mutation and gain, KDR gain, and activation of B-Raf non-V600 (elevated phosphorylation S445) for SM0014 whose tumor demonstrated a BRAF fusion and gain and for whom binimetinib was selected as the treatment recommendation. Here, KDR is linked to neoplasm.